Oruka Therapeutics shares are trading higher after Leerink Partners maintained its Outperform rating on the stock and raised its price target from $58 to $86.

Benzinga Newsdesk www.benzinga.com Positive 95.3%

Neg 0% Neu 0% Pos 95.3%

Comments

No comments yet. Be the first!